Manufacturing capacity constraints and bio-based shifts pressure microencapsulation supply chains

High capital and scalability costs for advanced techniques like high-NA spray and continuous coacervation are creating processing bottlenecks for smaller formulators and CMOs. Simultaneously, increasing regulatory scrutiny surrounding synthetic microplastics is accelerating the mandatory transition toward natural, bio-based wall matrices. These compounding developments require procurement teams to navigate tighter production slots and re-validate alternative formulations.